Jeffrey P Henderson

List of Publications by Year
in descending order

52	3,267	186265	197818
papers	citations	28 h-index	49 g-index

59	59	59	5607
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host and Microbe, 2020, 28, 475-485.e5.	11.0	380
2	The siderophore yersiniabactin binds copper to protect pathogens during infection. Nature Chemical Biology, 2012, 8, 731-736.	8.0	263
3	Quantitative Metabolomics Reveals an Epigenetic Blueprint for Iron Acquisition in Uropathogenic Escherichia coli. PLoS Pathogens, 2009, 5, e1000305.	4.7	211
4	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	7.1	149
5	Genomic Diversity and Fitness of E. coli Strains Recovered from the Intestinal and Urinary Tracts of Women with Recurrent Urinary Tract Infection. Science Translational Medicine, 2013, 5, 184ra60.	12.4	148
6	Structural engineering of a phage lysin that targets Gram-negative pathogens. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9857-9862.	7.1	144
7	The Heme Biosynthesis Pathway Is Essential for Plasmodium falciparum Development in Mosquito Stage but Not in Blood Stages. Journal of Biological Chemistry, 2014, 289, 34827-34837.	3.4	133
8	Phagocytes Produce 5-Chlorouracil and 5-Bromouracil, Two Mutagenic Products of Myeloperoxidase, in Human Inflammatory Tissue. Journal of Biological Chemistry, 2003, 278, 23522-23528.	3.4	128
9	Copper import in Escherichia coli by the yersiniabactin metallophore system. Nature Chemical Biology, 2017, 13, 1016-1021.	8.0	112
10	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clinical Chemistry, 2020, 66, 1538-1547.	3.2	112
11	Pathogenic adaptations to host-derived antibacterial copper. Frontiers in Cellular and Infection Microbiology, 2014, 4, 3.	3.9	103
12	Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice. Antimicrobial Agents and Chemotherapy, 2012, 56, 4738-4745.	3.2	94
13	Cupric Yersiniabactin Is a Virulence-Associated Superoxide Dismutase Mimic. ACS Chemical Biology, 2014, 9, 551-561.	3.4	91
14	The iron hand of uropathogenic Escherichia coli: the role of transition metal control in virulence. Future Microbiology, 2018, 13, 745-756.	2.0	77
15	Use of convalescent plasma in<scp>COVID</scp>â€19 patients with immunosuppression. Transfusion, 2021, 61, 2503-2511.	1.6	70
16	Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections. Journal of Clinical Investigation, 2019, 129, 3792-3806.	8.2	70
17	The Widely Used Antimicrobial Triclosan Induces High Levels of Antibiotic Tolerance In Vitro and Reduces Antibiotic Efficacy up to 100-Fold In Vivo. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	64
18	Both Host and Pathogen Factors Predispose to Escherichia coli Urinary-Source Bacteremia in Hospitalized Patients. Clinical Infectious Diseases, 2012, 54, 1692-1698.	5.8	59

#	Article	IF	Citations
19	Metal selectivity by the virulence-associated yersiniabactin metallophore system. Metallomics, 2015, 7, 1011-1022.	2.4	57
20	Microbial Copper-binding Siderophores at the Host-Pathogen Interface. Journal of Biological Chemistry, 2015, 290, 18967-18974.	3.4	56
21	Deconvoluting heme biosynthesis to target blood-stage malaria parasites. ELife, 2015, 4, .	6.0	55
22	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	2.6	50
23	SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. Journal of Clinical Investigation, 2021, 131, .	8.2	47
24	Uropathogenic enterobacteria use the yersiniabactin metallophore system to acquire nickel. Journal of Biological Chemistry, 2018, 293, 14953-14961.	3.4	46
25	Human Urinary Composition Controls Antibacterial Activity of Siderocalin*. Journal of Biological Chemistry, 2015, 290, 15949-15960.	3.4	45
26	Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic Escherichia coli. Journal of Proteome Research, 2014, 13, 1397-1404.	3.7	43
27	A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. Journal of Clinical Medicine, 2019, 8, 415.	2.4	37
28	Enterobacteria secrete an inhibitor of Pseudomonas virulence during clinical bacteriuria. Journal of Clinical Investigation, 2017, 127, 4018-4030.	8.2	34
29	The Bacterial Amyloid Curli Is Associated with Urinary Source Bloodstream Infection. PLoS ONE, 2014, 9, e86009.	2.5	33
30	Human Metabolome-derived Cofactors Are Required for the Antibacterial Activity of Siderocalin in Urine. Journal of Biological Chemistry, 2016, 291, 25901-25910.	3.4	31
31	Yersinia High Pathogenicity Island Genes Modify the Escherichia coli Primary Metabolome Independently of Siderophore Production. Journal of Proteome Research, 2011, 10, 5547-5554.	3.7	28
32	Low correlation between self-report and medical record documentation of urinary tract infection symptoms. American Journal of Infection Control, 2015, 43, 983-986.	2.3	20
33	Site-Specific Siderocalin Binding to Ferric and Ferric-Free Enterobactin As Revealed by Mass Spectrometry. ACS Chemical Biology, 2020, 15, 1154-1160.	3.4	20
34	Network Analysis Reveals Sex- and Antibiotic Resistance-Associated Antivirulence Targets in Clinical Uropathogens. ACS Infectious Diseases, 2015, 1, 523-532.	3.8	17
35	The Yersiniabactin-Associated ATP Binding Cassette Proteins YbtP and YbtQ Enhance Escherichia coli Fitness during High-Titer Cystitis. Infection and Immunity, 2016, 84, 1312-1319.	2.2	17
36	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. SSRN Electronic Journal, 2020, , 3606354.	0.4	16

#	Article	IF	Citations
37	Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis. ELife, 2022, 11, .	6.0	16
38	Organic Solvents for Enhanced Proteolysis of Stable Proteins for Hydrogenâ€“Deuterium Exchange Mass Spectrometry. Analytical Chemistry, 2020, 92, 11553-11557.	6.5	15
39	YbtT is a low-specificity type II thioesterase that maintains production of the metallophore yersiniabactin in pathogenic enterobacteria. Journal of Biological Chemistry, 2018, 293, 19572-19585.	3.4	14
40	Patient characteristics but not virulence factors discriminate between asymptomatic and symptomatic E. coli bacteriuria in the hospital. BMC Infectious Diseases, 2013, 13, 213.	2.9	13
41	The Yersinia High-Pathogenicity Island Encodes a Siderophore-Dependent Copper Response System in Uropathogenic Escherichia coli. MBio, 2022, 13, e0239121.	4.1	13
42	Clostridium difficile colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea. Infection Control and Hospital Epidemiology, 2018, 39, 1330-1333.	1.8	10
43	Assessment of serological assays for identifying high titer convalescent plasma. Transfusion, 2021, 61, 2658-2667.	1.6	7
44	Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv271.	3.0	6
45	WHO covid-19 drugs guideline: reconsider using convalescent plasma. BMJ, The, 2022, 376, o295.	6.0	6
46	Prevalence of Asymptomatic Bacteriuria in Hospitalized Patients. Infection Control and Hospital Epidemiology, 2016, 37, 749-751.	1.8	5
47	What are protective antibody responses to pandemic SARS-CoV-2?. Journal of Clinical Investigation, 2020, 130, 6232-6234.	8.2	5
48	A mass spectrometry based transport assay for studying EmrE transport of unlabeled substrates. Analytical Biochemistry, 2018, 549, 130-135.	2.4	3
49	Individualizing Urinary Incontinence Treatment: Research Needs Identified at NIDDK Workshop. Journal of Urology, 2018, 199, 1405-1407.	0.4	2
50	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. SSRN Electronic Journal, 0, , .	0.4	2
51	Identification of Mutasynthetic Inhibitors of Yersiniabactin Production in Uropathogenic E. coli. FASEB Journal, 2021, 35, .	0.5	0
52	Ni(II) Uptake by Yersiniabactin, a Metallophore Produced by Uropathogenic E. coli. FASEB Journal, 2018, 32, 669.21.	0.5	0